When to start an aromatase inhibitor: Now or later?
Version of Record online: 24 FEB 2011
Copyright © 2011 Wiley-Liss, Inc.
Journal of Surgical Oncology
Volume 103, Issue 7, pages 730–738, 1 June 2011
How to Cite
Doughty, J. C. (2011), When to start an aromatase inhibitor: Now or later?. J. Surg. Oncol., 103: 730–738. doi: 10.1002/jso.21801
- Issue online: 26 APR 2011
- Version of Record online: 24 FEB 2011
- Manuscript Accepted: 22 OCT 2010
- Manuscript Received: 17 MAY 2010
- adjuvant endocrine therapy;
- distant metastases;
- hormonal treatment;
- recurrence risk;
Among women who have undergone surgery for breast cancer, the risk of recurrence, especially distant metastases, peaks 1–2 years postsurgery. Recent clinical trial evidence suggests that initial adjuvant therapy with an aromatase inhibitor (AI) can reduce this early risk of recurrence. According to the recently updated St Gallen consensus statement, initial AI therapy is the preferred strategy for adjuvant endocrine therapy in postmenopausal women with hormone receptor-positive breast cancer. J. Surg. Oncol. 2011;103:730–738. © 2011 Wiley-Liss, Inc.